S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
- Authors:
- Yuki Tomita
- Tetsuya Oguri
- Osamu Takakuwa
- Makoto Nakao
- Eiji Kunii
- Takehiro Uemura
- Hiroaki Ozasa
- Mikinori Miyazaki
- Ken Maeno
- Shigeki Sato
View Affiliations
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan
- Published online on: December 1, 2011 https://doi.org/10.3892/ol.2011.507
-
Pages:
405-410
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
View References
|
1
|
Shirasaka T, Nakano K, Takechi T, et al:
Antitumor activity of 1 M tegafur-0.4 M
5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against
human colon carcinoma orthotopically implanted into nude rats.
Cancer Res. 56:2602–2606. 1996.
|
|
2
|
Kawahara M, Furuse K, Segawa Y, et al:
Phase II study of S-1, a novel oral fluorouracil, in advanced
non-small-cell lung cancer. Br J Cancer. 85:939–943. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okamoto I, Yoshioka H, Morita S, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naïve patients with advanced
non-small-cell lung cancer: results of a West Japan Oncology Group
study. J Clin Oncol. 28:5240–5246. 2010.PubMed/NCBI
|
|
4
|
Takakuwa O, Oguri T, Maeno K, et al:
Efficacy of S-1 monotherapy for non-small cell lung cancer after
the failure of two or more prior chemotherapy regimens. Oncol Lett.
1:147–150. 2010.PubMed/NCBI
|
|
5
|
Nishiyama O, Taniguchi H, Kondoh Y, et al:
Phase II study of S-1 monotherapy as a first-line treatment for
elderly patients with advanced nonsmall-cell lung cancer: the
Central Japan Lung Study Group trial 0404. Anticancer Drugs.
22:811–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oguri T, Achiwa H, Bessho Y, et al: The
role of thymidylate synthase and dihydropyrimidine dehydrogenase in
resistance to 5-fluorouracil in human lung cancer cells. Lung
Cancer. 49:345–351. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oguri T, Bessho Y, Achiwa H, et al:
MRP8/ABCC11 directly confers resistance to 5 fluorouracil. Mol
Cancer Ther. 6:122–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giovannetti E, Mey V, Nannizzi S, et al:
Cellular and pharmacogenetics foundation of synergistic interaction
of pemetrexed and gemcitabine in human non-small-cell lung cancer
cells. Mol Pharmacol. 68:110–118. 2005.PubMed/NCBI
|
|
10
|
Ozasa H, Oguri T, Uemura T, et al:
Significance of thymidylate synthase for resistance to pemetrexed
in lung cancer. Cancer Sci. 101:161–166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gomez HL, Santillana SL, Vallejos CS, et
al: A phase II trial of pemetrexed in advanced breast cancer:
clinical response and association with molecular target expression.
Clin Cancer Res. 12:832–838. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scagliotti G, Hanna N, Fossella F, et al:
The differential efficacy of pemetrexed according to NSCLC
histology: a review of two phase III studies. Oncologist.
14:253–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
